AIRS — AirSculpt Technologies, Inc.

AIRS Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $35 million, down 17.8% year-over-year; lower than anticipated due to timing issues.
• Same-store Revenue: Declined approximately 22%.
• Cases: Total cases decreased by 15.2% to 2,780; same-store cases down approximately 20%.
• Average Revenue per Case: $12,587, a decline of about 3% from the prior year but within historical range.
• Adjusted EBITDA: $3 million, down from $4.7 million; adjusted EBITDA margin at 8.7% compared to 11% last year.
• Net Loss: $9.5 million; adjusted net loss of $2.4 million or $0.04 per diluted share.
• Cash Position: $5.4 million; gross debt of $57.9 million with a leverage ratio of 3.04x.
• Cost Management: SG&A expenses decreased by $6 million; $3 million in annualized cost savings achieved.

2. Strategic Updates and Business Highlights:

• GLP-1 Market Opportunity: AirSculpt is focusing on new services to address the aesthetic needs of GLP-1 medication users, which is expected to be a significant growth driver.
• New Services: Expansion of skin tightening procedures and introduction of skin excisions to cater to patients with loose skin post-weight loss.
• Sales and Marketing Strategy: Adjustments made to marketing spend to improve conversion rates; emphasis on affluent consumer targeting and diversified media mix.
• Debt Reduction: Nearly $18 million repaid year-to-date, with a focus on strengthening the balance sheet.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Updated to approximately $153 million, down from previous guidance of $160-$170 million.
• 2025 EBITDA Guidance: Reiterated at approximately $16 million, at the lower end of the previous range.
• Q4 Expectations: Improvement in same-store sales performance anticipated, with stronger margins expected in Q4 compared to year-to-date.

4. Bad News, Challenges, or Points of Concern:

• Revenue Decline: Significant year-over-year revenue drop and same-store sales decline indicate ongoing challenges in consumer purchasing behavior.
• Market Conditions: Continued hesitance among consumers to convert interest into purchases, particularly in a challenging economic environment.
• Operational Challenges: Closure of the London center, which was unprofitable, leading to impairment charges.
• Noncash Charges: Impairment related to the Salesforce project and operational costs associated with the London closure negatively impacted financials.

5. Notable Q&A Insights:

• Cost Controls: Management indicated strong cost control measures, primarily in SG&A, are expected to continue into Q4 and beyond.
• Skin Tightening Demand: Initial demand for skin tightening procedures is promising, but many patients require additional procedures for loose skin, leading to a broader service offering.
• Surgeon Interest: High interest among surgeons for new procedures targeting GLP-1 users, with confidence in their capabilities to perform skin excisions.
• Marketing Strategy Adjustments: Plans to refine messaging and targeting for GLP-1 users to enhance brand awareness and drive conversions.

Overall, while AirSculpt is facing short-term revenue challenges, it is strategically positioning itself to capitalize on emerging market opportunities related to GLP-1 medications, with a focus on operational efficiency and financial discipline.